DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme November 17, 2014
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 as a Potential New Treatment in Glioblastoma at the Society of Neuro-Oncology Annual Meeting November 14, 2014
DelMar Pharmaceuticals Announces September 30, 2014 Results and Provides Corporate Update November 10, 2014
DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting November 6, 2014
DelMar Pharmaceuticals to Present at the SeeThruEquity Fall Microcap Investor Conference September 4, 2014
DelMar Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent for VAL-083 September 3, 2014
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments August 29, 2014
